Open access

341 Phase 1b/2 study of BXCL701, an oral activator of the systemic innate immunity pathway, combined with pembrolizumab (pembro), in men with metastatic castration-resistant prostate cancer (mCRPC)
Rahul Aggarwal, Dan Costin, Jingsong Zhang, Paul Monk, Mark Linch, Lawrence Karsh, Diane Healey, Stefani Corsi-Travali, Sreenivas Adurthi, Adedayo Adedoyin, Vincent O’Neill

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A208-A209; DOI: 10.1136/jitc-2020-SITC2020.0341
343 Phase 3 study of pembrolizumab + docetaxel and prednisone/prednisolone for metastatic castration-resistant prostate cancer (mCRPC) pretreated with next-generation hormonal agents (NHAs) (KEYNOTE-921)
Daniel Petrylak, Neal Shore, Mostefa Bennamoun, Raffaele Ratta, Josep Piulats, Ben Li, Charles Schloss, Karim Fizazi

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A209-A210; DOI: 10.1136/jitc-2020-SITC2020.0343
36 Molecular events regulating solid tumor cell responses to natural killer cells
Michal Sheffer, Constantine Mitsiades

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A21-A22; DOI: 10.1136/jitc-2020-SITC2020.0036
344 Phase 3 trial of pembrolizumab and enzalutamide versus enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) (KEYNOTE-641)
Julie Nicole Graff, Joseph Burgents, Li Wen Liang, Arnulf Stenzl

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A210; DOI: 10.1136/jitc-2020-SITC2020.0344
345 Phase 3 study of combination pembrolizumab + olaparib therapy versus enzalutamide/abiraterone in metastatic castration-resistant prostate cancer (mCRPC) after progression on chemotherapy (KEYLYNK-010)
Evan Yu, Se Hoon Park, Yi-Hsiu Huang, Mostefa Bennamoun, Lu Xu, Jeri Kim, Emmanuel Antonarakis

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A210-A211; DOI: 10.1136/jitc-2020-SITC2020.0345
346 KEYNOTE-991: phase 3 study of pembrolizumab plus enzalutamide and androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
Christian Gratzke, Christian Gratzke, Christian Gratzke, Cuizhen Niu, Christian Poehlein, Joseph Burgents

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A211; DOI: 10.1136/jitc-2020-SITC2020.0346
356 Baseline PD-L1 expression and tumor immune infiltration is associated with clinical response in patients with r/r DLBCL treated with DPX-Survivac, low-dose cyclophosphamide and pembrolizumab
Neil Berinstein, Isabelle Bence-Bruckler, Nick Forward, Pierre Laneuville, Joy Mangel, Douglas Stewart, Irina Amitai, Gail Klein, Nancy Pennell, Iran Rashedi, Kim Roos, Yogesh Bramhecha, Rebekah Conlon

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A217-A218; DOI: 10.1136/jitc-2020-SITC2020.0356
357 TAK-573, an anti-CD38–attenuated interferon alpha (IFNα) fusion protein (Attenukine™), has demonstrated IFNα receptor (IFNAR) pathway modulation in patients with relapsed/refractory multiple myeloma
Sabrina Collins, Adarsh Joshi, Lei Shen, Subhasree Das, Kaveri Suryanarayan, Dean Bottino, Cheryl Li, Michael Curley, Dannie Wang, Michael Abadier, Ryan Larson, Xavier Parot

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A218; DOI: 10.1136/jitc-2020-SITC2020.0357
358 Trial in progress: A pilot study of combined immune checkpoint inhibition in combination with ablative therapies in subjects with hepatocellular carcinoma (HCC)
Hailey Carroll, Umair Aleem, Pooja Varghese, Marie Galligan, Michèle Bourke, Katherine Hoey, Ronan Ryan, Peter Doran, Stephen Stewart, Cliona O’Farrelly, Tim Greten, Diarmaid Houlihan, Raymond McDermott, Austin Duffy

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A218-A219; DOI: 10.1136/jitc-2020-SITC2020.0358
359 AMG 757, a half-life extended bispecific T-cell engager (BiTE®) immune therapy against DLL3 in SCLC: phase 1 interim results
Hossein Borghaei, Michael Boyer, Melissa Johnson, Ramaswamy Govindan, Luis Paz-Ares Rodrigues, Fiona Blackhall, Rene Boosman, Stéphane Champiat, Horst-Dieter Hummel, W Victoria Lai, Hibiki Udagawa, Anne Chiang, Afshin Dowlati, Christine Hann, Ravi Salgia, Everett Vokes, Mukul Minocha, Nooshin Hashemi-Sadraei, Aditya Shetty, Marie-Anne Damiette Smit, Hui Yang, Taofeek Owonikoko

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A219-A220; DOI: 10.1136/jitc-2020-SITC2020.0359

Main menu

Open access

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Open access

Pages